EHA 2022 | IMpactMF: imetelstat vs best available therapy in patients with myelofibrosis
John Mascarenhas, MD, The Mount Sinai Hospital, New York, NY, gives an update on the IMpactMF (MYF3001; NCT04576156) – an open-label, randomized (2:1), multicenter, Phase III study of imetelstat compared with best available therapy in patients with intermediate 2 or high-risk myelofibrosis refractory to JAK inhibitor treatment. The study is currently open for enrolment and is planned across 180 sites in North and South America, Europe, Middle East, Australia and Asia. The primary endpoint of the study is overall survival – with an interim analysis planned when more than 71% of death events have occurred. Secondary endpoints include symptom and spleen response rates at week 24 and progression-free survival (PFS), amongst others. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Roche, BMS, Celgene, CTI Bio, Merck, PharmaEssentia, Abbvie, Kartos, Geron and consulting fees from Incyte, Celgene, BMS, Constellation, CTI Bio, Geron, Abbvie, Kartos, Novartis, Roche, Imago, Karyopharm, Galecto and PharmaEssentia.
